Thomas Cluzeau

39PUBLICATIONS
270CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical biotechnology diagnostics (incl. biosensors)Liquid biopsiesMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Oct 27, 2026
Prognostic Impact of FLT3-ITD Allelic Ratio in AML Patients Treated With High-Dose Anthracycline and a FLT3 Inhibitor.

|Sep 24, 2026
Outcome after first relapse post-immunochemotherapy in older adults with Philadelphia-negative B-cell acute lymphoblastic leukemia: A GRAALL study.

|Sep 18, 2026
Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia.

|Sep 01, 2026
Relationship Between Salvage Strategy and Outcomes in Patients With CBF or NPM1-mutated AML and First Molecular Relapse.

|Aug 26, 2026
Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.

|Jun 24, 2026
Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

Pageof 7

Frequent Collaborators

9 joint publications

Christian Recher

8 joint publications

Lionel Adès

7 joint publications

Rami S Komrokji

6 joint publications

Nicolas Duployez